Shigru Patra Arka preparation and clinical trial in Allergic conjuntivitis

Phase 4

• Conditions: Health Condition 1: H109- Unspecified conjunctivitis

• Registration Number: CTRI/2024/01/061729
• Lead Sponsor: Dr Anjali Avinash Khose

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1 Patients presenting with simple allergic conjunctivitis with established signs and symptoms of itching, redness, oedema and watering with eosiniphilia will be subjected for detailed anterior segment examination using slit lamp biomicroscope for diagnosis

2 Either gender and socioeconomic status

Exclusion Criteria

1 Patient suffering from other forms of allergic conjunctivitis like keratoconjunctivitis sicca, atropic keratoconjunctivitis, giant papillary conjunctivitis, drug or material senstivity, perennial allergic conjunctivitis etc.

2 Patients having severe conditions of ocular surface disorders

3 Patients having complicated eye diseases like Trachoma, Trichiasis, Steven Johnson syndrome, Synechiae etc will be excluded

4 Patient suffering from bacterial, viral, chlamydial, parasitic and all other types of conjunctivitis (contagious & non contagious)

5 Patients suffering from corneal ulcers, opacities, trauma, foreign bodies, OSD, etc

6 Conjunctival epitheliopathies like Pterygium, Pseudo-pterygium, Tumours, Retention cysts

7 Diagnosed cases of Glaucoma, retinopathies, optic neuritis, dry eye and who are under long term topical ocular drug therapies for any ophthalmic infective conditions

8 Extremely debilitated patients, pregnant ladies those who are working with on- screen professions

9 Specific systemic disorders like Renal pathologies, Uncontrolled Diabetes, Hypertension, and Hyperlipidaemia, Cardiovascular diseases, etc

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The results of reduction in signs and symptoms of itching, redness, watering and oedema by Eyedrop Shigrupatra Arka and Eyedrop Naphazoline hydrochloride (0.025%) with Pheniramine maleate (0.3%) are comparable.Timepoint: Day 01(before treatment), Day 15(during treatment), Day 22 (after treatment), Day 36 (follow up)

Secondary Outcome Measures

Name	Time	Method
ILTimepoint: NI